Hematology ·
TKI exposure linked to lower AML transformation in systemic mastocytosis with myeloid neoplasm
An international registry analysis of 201 patients with systemic mastocytosis and an associated hematologic neoplasm found that KIT D816V-selective TKI exposure was associated with longer overall survival and less AML transformation. The observational findings do not establish that TKI treatment caused these differences.
- Registry analysis included 201 patients with SM-AHN
- TKI exposure was associated with longer overall survival
- AML transformation incidence was lower at 36 months
- Observational findings do not establish causality
An international registry analysis included 201 patients with systemic mastocytosis with an associated hematologic neoplasm (SM-AHN). The analysis examined outcomes in relation to exposure to KIT D816V-selective tyrosine kinase inhibitors (TKIs), including overall survival and transformation to acute myeloid leukemia (AML).
Median overall survival was 37.9 months among patients exposed to a KIT D816V-selective TKI versus 17.8 months among those not exposed (P<.001). The 36-month cumulative incidence of AML transformation was 5.9% versus 27.1%, respectively (P<.001).
These registry findings show an association, not evidence that TKI exposure caused improved outcomes. The available source does not provide details on patient selection, treatment regimens, adjustment for confounding, or specific drugs, limiting assessment of applicability and clinical implications.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Blood: Tyrosine kinase inhibitors are associated with reduced AML transformation in systemic mastocytosis with myeloid neoplasm ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.